NCT00360867View on ClinicalTrials.gov

An Open Label Treatment Extension Study of AMG 706

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Solid Tumors

Interventions

DRUG

AMG 706

The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.